Edit
Business Wire
06 Nov 2013
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/7dqm7n/gastric_motility) has announced the addition of the "Gastric Motility Disorder - Pipeline Review, H2 2013" report to their offering. 'Gastric Motility Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline ... ... Drug Profiles TZP-102 velusetrag ipamorelin TD-8954 Drug For Bowel Motility Disorders ... ....(size: 4.6Kb)
Edit
Business Wire
26 Jun 2013
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/c28jjb/gastric_motility) has announced the addition of the "Gastric Motility Disorder - Pipeline Review, H1 2013" report to their offering. “Gastric Motility Disorder - Pipeline Review, H1 2013” ... Scope ... - Key discontinued pipeline projects ... Drug Profiles RM-131 ulimorelin hydrochloride TZP-102 velusetrag ipamorelin TD-8954 ... U.S ... ....(size: 4.3Kb)
Edit
Seeking Alpha
25 Apr 2013
Velusetrag. Velusetrag, an oral, investigational medicine dosed once daily, is a highly selective agonist with high intrinsic activity at the human 5-HT4 receptor. In October 2012, we entered into an exclusive development and commercialization agreement with Alfa Wassermann for velusetrag, our lead compound in the 5-HT4 program, covering the EU, Russia, China, Mexico and certain other countries....(size: 25.4Kb)
Edit
noodls
25 Apr 2013
Velusetrag. Velusetrag, an oral, investigational medicine dosed once daily, is a highly selective agonist with high intrinsic activity at the human 5-HT4 receptor. In October 2012, we entered into an exclusive development and commercialization agreement with Alfa Wassermann for velusetrag, our lead compound in the 5-HT4 program, covering the EU, Russia, China, Mexico and certain other countries....(size: 25.2Kb)
Edit
Seeking Alpha
12 Feb 2013
In addition, we continue to progress our internal programs, including Phase 2 studies in fibromyalgia and ADHD with TD-9855, a Phase 2b study in COPD with TD-4208, and a Phase 2 study in gastroparesis with velusetrag ... Velusetrag. Velusetrag, an oral, investigational medicine dosed once daily, is a highly selective agonist with high intrinsic activity at the human 5-HT4 receptor....(size: 23.5Kb)
Edit
noodls
12 Feb 2013
In addition, we continue to progress our internal programs, including Phase 2 studies in fibromyalgia and ADHD with TD-9855, a Phase 2b study in COPD with TD-4208, and a Phase 2 study in gastroparesis with velusetrag ... Velusetrag. Velusetrag, an oral, investigational medicine dosed once daily, is a highly selective agonist with high intrinsic activity at the human 5-HT4 receptor....(size: 23.9Kb)
Edit
StreetInsider
18 Jan 2013
Company Has Also Entered Into Capped Call Transactions in Connection With the Notes Offering. Tweet. Get Alerts THRX Hot Sheet. Price. $20.97 -7.78%. Overall Analyst Rating.. NEUTRAL ( Up). Revenue Growth %. -78.1% ... (NASDAQ ... Glaxo (GSK), Thervance (THRX) Submit App for UMEC/VI to EU Theravance (THRX), Alfa Wassermann Begin Velusetrag Phase 2 GSK and Theravance Announce Regulatory Submission for ANORO(TM) (UMEC/VI) in Europe. ....(size: 9.4Kb)
Edit
StreetInsider
16 Jan 2013
Company Intends to Use a Portion of the Net Proceeds of the Offering to Pay for the Cost of Entering Into Capped Call Transactions. Tweet. Get Alerts THRX Hot Sheet. Price. $22.74 -3.23%. Overall Analyst Rating. ... 0.0% ... Theravance (THRX), Alfa Wassermann Begin Velusetrag Phase 2 Theravance and Alfa Wassermann Announce Initiation of Phase 2 Study With Velusetrag for Gastroparesis Glaxo (GSK), Thervance (THRX) Submit App for UMEC/VI to EU. ....(size: 8.7Kb)
Edit
PR Newswire
11 Jan 2013
My news for Investors. AtLeast one of the check box should be selected You are following news about Follow the latest news about GSK. Follow the latest news about MRK. Follow the latest news about SNY. Follow the latest news about NVS. Follow the latest news about THRX. Google. Download image. CHICAGO, Jan ... NVS) ... n~32) to evaluate Theravance's pipeline candidate velusetrag in patients suffering from diabetic or idiopathic gastroparesis....(size: 9.9Kb)
Edit
StreetInsider
10 Jan 2013
Tweet. Get Alerts UTSI Hot Sheet. Price. $1.09 --0%. Overall Analyst Rating.. BUY (= Flat). Revenue Growth %. -55.6%. UTStarcom Holdings Corp. (Nasdaq ... Jefferies & Company, Inc ... You May Also Be Interested In. UTStarcom Announces Final Results of Its Tender Offer Progress Energy Selects TransCanada (TRP) to Run Large Nat Gas Project Theravance (THRX), Alfa Wassermann Begin Velusetrag Phase 2. ....(size: 2.0Kb)
Edit
StreetInsider
09 Jan 2013
announced today the initiation of a Phase 2 proof-of-concept study with velusetrag, Theravance's investigational 5-HT4 agonist, for the treatment of patients with ......(size: 0.9Kb)
Edit
StreetInsider
09 Jan 2013
Tweet. Get Alerts THRX Hot Sheet. Price. $21.72 --0%. Overall Analyst Rating.. NEUTRAL ( Up). Revenue Growth %. -78.1%. GlaxoSmithKline plc (NYSE. GSK) and Theravance, Inc ... Theravance (THRX), Alfa Wassermann Begin Velusetrag Phase 2 Boehringer, Lilly (LLY) Complete Four Phase 3s for Empagliflozin; Safety Profile Akin to Phase 2 Theravance and Alfa Wassermann Announce Initiation of Phase 2 Study With Velusetrag for Gastroparesis. ....(size: 2.7Kb)
